This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where ...

For example, the AbbVie Inc. (NYSE:ABBV) share price has soared 101% in the last half decade. Most would be very happy with ...

Boltwood Capital Management decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% in the 4th quarter, ...

BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...